ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,706.20
1.26%
Gold vs US Dollar
2,301.015
-0.11%
Brent Oil
83.045
-0.70%
Bitcoin
61,861.38
4.63%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Moberg Pharma Ab (publ) (0P48)

  7. Moberg Pharma Ab (publ) (0P48) News

Moberg Pharma Ab (publ) (0P48)

Moberg Pharma Ab (publ)
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0P48
DateTimeSourceHeadlineSymbolCompany
07/02/202407:12UK RegulatoryMOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medicationLSE:0P48Moberg Pharma Ab (publ)
07/02/202407:10UK RegulatoryMOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medicationLSE:0P48Moberg Pharma Ab (publ)
28/06/202310:23PR Newswire (US)MOB-015 is recommended for approval in EU: Moberg PharmaLSE:0P48Moberg Pharma Ab (publ)
28/03/202207:10PR Newswire (US)European marketing authorization application for MOB-015 submittedLSE:0P48Moberg Pharma Ab (publ)
23/12/202107:12PR Newswire (US)The Medical Products Agency in Sweden will be reference member state for Moberg Pharma's European registration applicationLSE:0P48Moberg Pharma Ab (publ)
22/09/202107:22PR Newswire (US)Moberg Pharma receives approval from the EMA's Paediatric CommitteeLSE:0P48Moberg Pharma Ab (publ)
09/02/202107:13PR Newswire (US)Moberg Pharmas Year-end report 2020LSE:0P48Moberg Pharma Ab (publ)
29/01/202112:23PR Newswire (US)Moberg Pharma: Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record...LSE:0P48Moberg Pharma Ab (publ)
29/01/202107:37PR Newswire (US)New number of shares and votes in Moberg Pharma AB (publ)LSE:0P48Moberg Pharma Ab (publ)
07/01/202107:08PR Newswire (US)OncoZenge announces issue of European Patent related to BupiZenge®LSE:0P48Moberg Pharma Ab (publ)
11/12/202007:07PR Newswire (US)OncoZenge raises MSEK 10 ahead of spin-off and separate listingLSE:0P48Moberg Pharma Ab (publ)
30/11/202013:33PR Newswire (US)Moberg Pharma obtains positive decision from the Swedish Tax Agency regarding the Lex Asea distribution of the shares in Onco...LSE:0P48Moberg Pharma Ab (publ)
23/11/202007:41PR Newswire (US)Invitation to market update in Moberg Pharma on November 25thLSE:0P48Moberg Pharma Ab (publ)
16/11/202014:16PR Newswire (US)OncoZenge secures approximately SEK 70 million in financing ahead of spin-off and separate listingLSE:0P48Moberg Pharma Ab (publ)
10/11/202008:02PR Newswire (US)Extended fiscal year July 2019 - December 2020 Interim report July - September 2020LSE:0P48Moberg Pharma Ab (publ)
06/11/202007:26PR Newswire (US)Moberg Pharma decides on fully guaranteed rights issue of approximately SEK 150 millionLSE:0P48Moberg Pharma Ab (publ)
06/11/202007:25PR Newswire (US)Moberg Pharma intends to distribute and separately list BupiZenge® (BUPI)LSE:0P48Moberg Pharma Ab (publ)
14/10/202007:27PR Newswire (US)Moberg Pharma intends to submit a registration application in Europe in 2021LSE:0P48Moberg Pharma Ab (publ)
14/10/202007:24PR Newswire (US)Moberg Pharma intends to submit a registration application in Europe in 2021LSE:0P48Moberg Pharma Ab (publ)
11/08/202007:16PR Newswire (US)Moberg Pharma: Interim report April - June 2020LSE:0P48Moberg Pharma Ab (publ)
30/07/202007:27PR Newswire (US)Appointment of Chief Medical Officer at Moberg PharmaLSE:0P48Moberg Pharma Ab (publ)
30/06/202007:28PR Newswire (US)New number of Shares and Votes in Moberg Pharma AB (publ)LSE:0P48Moberg Pharma Ab (publ)
25/06/202007:26PR Newswire (US)Moberg Pharma Meets Primary Endpoint in the European Phase 3 StudyLSE:0P48Moberg Pharma Ab (publ)
25/06/202007:23PR Newswire (US)Moberg Pharma Meets Primary Endpoint in the European Phase 3 StudyLSE:0P48Moberg Pharma Ab (publ)
29/05/202007:13PR Newswire (US)New Number of Shares and Votes in Moberg Pharma AB (publ)LSE:0P48Moberg Pharma Ab (publ)
12/05/202007:24PR Newswire (US)Extended Fiscal Year July 2019 - December 2020 Interim Report January - March 2020LSE:0P48Moberg Pharma Ab (publ)
05/05/202007:14PR Newswire (US)Moberg Pharma's Interim Report for July 2019 - March 2020 to be Published on May 12 - Invitation to TeleconferenceLSE:0P48Moberg Pharma Ab (publ)
27/03/202008:20PR Newswire (US)Notice of Extraordinary General Meeting in Moberg Pharma AB (publ)LSE:0P48Moberg Pharma Ab (publ)
23/03/202020:17PR Newswire (US)Moberg Pharma Enters Financing Agreement of Up To SEK 216 Million for Further Investments in MOB-015LSE:0P48Moberg Pharma Ab (publ)
11/02/202007:18PR Newswire (US)Moberg Pharma AB Interim Report October - December 2019LSE:0P48Moberg Pharma Ab (publ)
 Showing the most relevant articles for your search:LSE:0P48

Your Recent History

LSE
TERN
Tern
LSE
AGL
Angle
LSE
POS
Plexus
LSE
AAZ
Anglo Asian Mining
LSE
BIRD
Blackbird
LSE
SCE
Surface Transforms
LSE
PHNX
Phoenix
LSE
BT.A
Bt
LSE
SCLP
Scancell
LSE
AAU
Ariana Resources
LSE
IES
Invinity Energy Systems
LSE
ZPHR
Zephyr Energy
LSE
DELT
Deltic Energy
LSE
VAST
Vast Resources
LSE
LLOY
Lloyds Banking
LSE
GOLD
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved